FDA extended the action date for the supplemental Biologics License Application for Keytruda (pembrolizumab) for previously treated patients with advanced microsatellite instability-high cancer.
Mylan N.V. announced that the company has agreed to the terms of a global settlement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. in relation to patents for Herceptin (trastuzumab), which provides Mylan with global licenses for its trastuzumab product.
Oncoceutics Inc. announced research collaborations with various groups within the NIH to study DRD2 as a novel therapeutic target in oncology.
Marshall Hicks was named interim president of MD Anderson Cancer Center.
Roger Stupp, a Swiss neuro-oncologist, was named associate director for strategic initiatives at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Arti Hurria, City of Hope's new vice provost, plans to focus on faculty growth and development, including fostering faculty career development and ensuring more diverse voices are represented.
Gwen Nichols was named chief medical officer of the Leukemia & Lymphoma Society.
David Penson was named chair of the Science & Quality Council at the American Urological Association. He will assume the role of chair-elect on June 1 and begin his two-year term as chair on June 2018.
NCI awarded ATCC a five-year indefinite-delivery/indefinite-quantity contract to support the Division of Cancer Epidemiology and Genetics' Molecular Epidemiology Assay Support program.
The International Labour Organization voted on Wednesday to delay the decision on whether to cut ties with Big Tobacco until November.
